News
OGN
6.36
+3.58%
0.22
Can VTAMA’s New AD Data Offset Earnings Weakness in Shaping Organon’s (OGN) Dermatology Strategy?
Simply Wall St · 7h ago
Weekly Report: what happened at OGN last week (0323-0327)?
Weekly Report · 5d ago
Evaluating Organon (OGN) After A Steep Share Price And One Year Return Decline
Simply Wall St · 5d ago
Organon accelerates Women's Health progress across Asia Pacific with 2026 Her Health Grants
PR Newswire · 5d ago
Organon to present results from Phase 3 Adoring 1, Adoring 2 on Vtama cream
TipRanks · 03/27 12:10
Organon To Present Results Of Post-Hoc Sub-Analysis Of Pooled Data From Phase 3 ADORING 1 And ADORING 2 Pivotal Trials Evaluating Efficacy And Safety Of VTAMA Cream Versus Vehicle At AAD Annual Meeting
Benzinga · 03/27 12:07
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age
Barchart · 03/27 07:00
Is It Time To Reassess Organon (OGN) After Its Sharp Share Price Slide
Simply Wall St · 03/27 05:07
Weekly Report: what happened at OGN last week (0316-0320)?
Weekly Report · 03/23 09:14
3 Cash-Producing Stocks We’re Skeptical Of
Barchart · 03/23 04:08
Assessing Organon (OGN) Valuation After Prolonged Share Price Weakness And A 33% Undervaluation Estimate
Simply Wall St · 03/21 20:08
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?
The Motley Fool · 03/20 21:42
Organon leads ultra-low P/E stocks at 1.8x as small-cap stocks face volatility
Seeking Alpha · 03/18 17:25
PJP: Healthcare Dashboard For March
Seeking Alpha · 03/17 09:12
Weekly Report: what happened at OGN last week (0309-0313)?
Weekly Report · 03/16 09:14
Is Organon (OGN) Mispriced After A 58% One Year Share Price Slump?
Simply Wall St · 03/14 07:30
3 of Wall Street’s Favorite Stocks We Approach with Caution
Barchart · 03/13 03:36
Organon trades in red for seven straight sessions
Seeking Alpha · 03/10 17:52
Weekly Report: what happened at OGN last week (0302-0306)?
Weekly Report · 03/09 09:14
Can VTAMA’s Pediatric Sleep Data Nudge Organon (OGN) Toward a Stronger Dermatology-Led Growth Identity?
Simply Wall St · 03/03 22:27
More
Webull provides a variety of real-time OGN stock news. You can receive the latest news about ORGANON & CO through multiple platforms. This information may help you make smarter investment decisions.
About OGN
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.